A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Recruiting · Phase 1 · NCT06258304
Conditions: Advanced or Metastatic Solid Tumor Malignancies
At a glance
- Research payments reported, 2025
- $330,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 60
About the trial
- Sponsor
- GigaGen, Inc. (with National Cancer Institute (NCI))
- Tested
- GIGA-564 (drug), GIGA-564 (drug)
- Dates
- Started 2024-05-08; completion 2027-11
- Results posted
- Not yet
The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.
From ClinicalTrials.gov, last updated 2025-04-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Grifols Shared Services North America, Inc. reported $330,000 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- National Cancer Institute $330,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.